Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Significant Increase in Short Interest

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 189,600 shares, a growth of 183.8% from the March 31st total of 66,800 shares. Based on an average daily volume of 2,030,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH initiated coverage on shares of Biodexa Pharmaceuticals in a report on Thursday, February 8th. They issued a “buy” rating and a $8.00 price target on the stock.

Biodexa Pharmaceuticals Stock Up 79.4 %

Shares of NASDAQ BDRX opened at $1.30 on Friday. Biodexa Pharmaceuticals has a 12 month low of $0.67 and a 12 month high of $21.38. The firm’s 50 day simple moving average is $1.16 and its 200-day simple moving average is $2.18.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.